Sponsor Directory

AstraZeneca clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 3:35 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1904

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Dyslipidemia
Interventions: AZD0780, Rosuvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Dyslipidaemia
Interventions: AZD0780, Itraconazole, Carbamazepine, Midazolam, Ethinyl estradiol/levonorgestrel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Neurofibromatosis 2, Vestibular Schwannoma, Meningioma, Ependymoma, Glioma
Interventions: Selumetinib; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 3 Years to 45 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: SARS-CoV-2
Interventions: AZD7442; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 0 Years to 17 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: Long Beach, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more

Conditions: Non-Small Cell Lung Cancer, Small Cell Lung Cancer
Interventions: Durvalumab, Cisplatin, Carboplatin, Etoposide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Houston, Texas • Fairfax, Virginia

Conditions: Advanced Haematological Malignancies
Interventions: AZD4573, Acalabrutinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 4
States / cities: Duarte, California • La Jolla, California • Houston, Texas + 1 more

Conditions: Renal Disease
Interventions: assessment; Procedure
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 2,575 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 17
States / cities: Huntsville, Alabama • Bakersfield, California • Chatsworth, California + 14 more

Conditions: Adenocarcinoma Gastric Stage IV With Metastases, Adenocarcinoma - GEJ
Interventions: Trastuzumab deruxtecan; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 20
States / cities: Duarte, California • Los Angeles, California • Monterey, California + 15 more

Conditions: Diabetes Mellitus, Type 2, Coronary Artery Disease
Interventions: Ticagrelor monotherapy, Ticagrelor plus aspirin, Clopidogrel with aspirin; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Colorectal Cancer Metastatic, Colon Cancer, Metastatic Colorectal Cancer, Rectal Cancer, Liver Metastasis Colon Cancer, Colo-rectal Cancer, Colorectal Adenocarcinoma, Colorectal Neoplasms, Liver Metastases, Colorectal Carcinoma
Interventions: Durvalumab, Yttrium-90 RadioEmbolization; Drug · Radiation
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 99 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Opioid Use Disorder
Interventions: AZD4041, Itraconazole, Buprenorphine, Buprenorphine / Naloxone, Hydromorphone, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatic Impairment
Interventions: Camizestrant; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 50 Years to 75 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: San Antonio, Texas

About this AstraZeneca sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AstraZeneca is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AstraZeneca trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AstraZeneca clinical trials

Filter and sort this sponsor

Live official records

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.

An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions

Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors

AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics

A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer

AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

A Study to Identify and Characterise Patients With Chronic Kidney Disease and Proteinuria

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus

Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer

Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).

Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects

About this AstraZeneca sponsor directory page